SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Pulmonology (asthma) Consultation — Mary McLeod Bethune

PatientMary McLeod Bethune
Date of birth1953-07-10
IdentifiersMRN HR-ML043-SYN; SSN (made up) 000-43-2195
Document date2026-03-23
AuthorSamuel Oyelowo-Brandt, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Four months of wheeze, night cough and breathlessness on stairs in a 72-year-old never-smoking woman who has been told for many years that she has asthma but has never had lung function testing and has been treated with albuterol alone. Please confirm or refute asthma with spirometry before and after bronchodilator, DLCO and FeNO, help separate it from COPD and heart disease, and advise on treatment. [S]

Urgency: Within two weeks. [S]

Questions for the consultant:

History of Present Illness

Mrs. Bethune, 72, is seen at the request of Dr. Harrington-Mbeki for four months of worsening wheeze, night cough and breathlessness on exertion, on a background of asthma diagnosed clinically many years ago and never confirmed. She uses albuterol most days and has never had an inhaled corticosteroid. Triggers are colds, dust, perfume and humid air. She has never smoked. She has nasal blockage, postnasal drip and reduced smell, and evening heartburn. She has had no oral corticosteroid course, emergency visit or admission for asthma in the past year. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid)Two puffs every 4 hours as needed; she uses it most daysRespiratory tract route2025-11-03 to 2026-03-23completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route2026-03-23 to 2026-06-15completedS
Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septumTwo sprays each nostril dailyNasal route2026-03-23activeS
Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid sprayTwo sprays each nostril up to four times dailyNasal route2026-03-23activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeksOne capsule daily before breakfastOral route2026-03-23 to 2026-05-18completedS

Problems

ProblemClinical statusVerificationCodeProvenance
Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram bookedresolvedconfirmed R06.2S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit.
Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialistactiveconfirmed R09.81S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy.
Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight lossactiveconfirmed K21.9S — Synthetic comorbidity of asthma; not a claim about her real health.
Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about itactiveconfirmed E66.811S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight.
Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol aloneactiveconfirmed J45.40S — Synthetic modern confirmation linked to her documented chronic asthma.
Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mLactiveconfirmed I11.9S — Synthetic finding of the modern work-up; not a claim about her real heart.
Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertensionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor.

Physical Exam

Vital signs recorded on 2026-03-23; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralComposed, speaking in full sentences; blood pressure 146/86, pulse 78; oxygen saturation 96 percent
NoseSwollen, pale inferior turbinates; no polyps visible by anterior rhinoscopy
RespiratoryScattered expiratory wheeze on forced expiration; no crackles
CardiovascularRegular rhythm; no gallop; jugular venous pressure not raised; no edema

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-23FEV1 --pre bronchodilation1.3LLower limit of normal, GLI Global race-neutral equations; predicted 2.03 LLowS
2026-03-23FEV1 --post bronchodilation1.57LLower limit of normal, GLI Global race-neutral equations; predicted 2.03 LNormalS
2026-03-23FEV1 measured/predicted64%GLI Global race-neutral equationsLowS
2026-03-23FEV1/FVC0.64{ratio}>=0.7LowS
2026-03-23FEV1/FVC --post bronchodilation0.72{ratio}0.70 or more after bronchodilator: no persistent airflow obstructionNormalS
2026-03-23Diffusion capacity.carbon monoxide17.2mL/min/mm[Hg]Lower limit of normal, GLI race-neutral; predicted 18.6NormalS
2026-03-23Fractional concentration of exhaled nitric oxide46[ppb]Above 50 ppb high; 25 to 50 intermediate (ATS)HighS
2026-03-23Left ventricular Ejection fraction62%53-73%NormalS
2026-03-23IgE [Units/volume] in Serum or Plasma210[IU]/mL<=100 [IU]/mLHighS
2026-03-23Total score [ACT]14{score}S

Assessment

Data reviewed: Dr. Harrington-Mbeki's intake note and results: chest X-ray with mild hyperinflation and normal heart size; ECG with LVH by voltage; blood eosinophils 0.42; BNP 48; Asthma Control Test 13. This morning, in our laboratory, with GLI Global race-neutral equations: FEV1 1.30 L (64 percent predicted) before and 1.57 L after albuterol 400 mcg (+270 mL, +21 percent); FEV1/FVC 0.64 before and 0.72 after; DLCO 17.2 (92 percent predicted); FeNO 46 ppb. Total IgE 210 IU/mL; specific IgE positive to house dust mite, negative to cat, dog, cockroach and mold. Transthoracic echocardiogram this morning: ejection fraction 62 percent, mild concentric LVH, grade 1 diastolic dysfunction, normal left atrium and right ventricle, estimated pulmonary artery systolic pressure 28 mmHg. [S]

Plan of Treatment